Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus mepolizumab in adults with relapsing or refractory EGPA
CTR20221099Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of depemokimab, mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by GSK. Started Sep 2022; status: completed.
02
Drugs
depemokimabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on CTR20221099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221099.